Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

Compare

184 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CNTA Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Centessa

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CNTA Stock 12 Month Forecast

Average Price Target

$34.50

▲(57.89% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Centessa Pharmaceuticals in the last 3 months. The average price target is $34.50 with a high forecast of $40.00 and a low forecast of $27.00. The average price target represents a 57.89% change from the last price of $21.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","24":"$24","41":"$41","15.5":"$15.5","32.5":"$32.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15.5,24,32.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.27,19.018461538461537,20.766923076923078,22.515384615384615,24.263846153846153,26.012307692307694,27.76076923076923,29.50923076923077,31.25769230769231,33.00615384615385,34.754615384615384,36.50307692307692,38.25153846153846,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.27,18.595384615384614,19.92076923076923,21.246153846153845,22.57153846153846,23.896923076923077,25.22230769230769,26.54769230769231,27.873076923076923,29.198461538461537,30.523846153846154,31.84923076923077,33.174615384615386,{"y":34.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.27,18.018461538461537,18.766923076923078,19.515384615384615,20.263846153846153,21.012307692307694,21.76076923076923,22.50923076923077,23.25769230769231,24.006153846153847,24.754615384615384,25.503076923076925,26.251538461538463,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$34.50

Lowest Price Target$27.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Risinger

Leerink Partners

$36

Buy

64.76%

Upside

Reiterated

09/11/25

Centessa Pharmaceuticals: Promising Prospects for ORX750 Justify Buy RatingWe anticipate disclosure of Ph2a results this fall, and we rate CNTA OP with a PT of $36.

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/09/25

Truist Financial Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)

Jay Olson

Oppenheimer

$40

Buy

83.07%

Upside

Reiterated

09/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (NASDAQ: VRDN), Cochlear (Other OTC: CHEOF) and Centessa Pharmaceuticals (NASDAQ: CNTA)We recently moved CNTA to Outperform from Perform.

Kostas Biliouris

BMO Capital

$35

Buy

60.18%

Upside

Reiterated

09/08/25

Centessa Pharmaceuticals: Buy Rating Based on Promising Orexin Agonist Program and Market Potential

Clara Dong

Jefferies

$19→$27

Buy

23.57%

Upside

Reiterated

09/08/25

Jefferies Remains a Buy on Centessa Pharmaceuticals (CNTA)

Francois Brisebois

LifeSci Capital

$37→$39

Buy

78.49%

Upside

Reiterated

09/08/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from LifeSci Capital

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

09/03/25

Evercore ISI Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Benjamin Burnett

Wells Fargo

$31

Buy

41.88%

Upside

Initiated

09/03/25

Centessa initiated with an Overweight at Wells FargoCentessa initiated with an Overweight at Wells Fargo

Ami Fadia

Needham

―

Buy

―

Reiterated

08/20/25

We reiterate our Buy rating and continue to have conviction that CNTA could emerge with the best in class profile based on its wide therapeutic index.

Biren Amin

Piper Sandler

$38

Buy

73.91%

Upside

Reiterated

08/18/25

Piper Sandler Remains a Buy on Centessa Pharmaceuticals (CNTA)

Rudy Li

Chardan Capital

$30

Buy

37.30%

Upside

Reiterated

08/12/25

Chardan Capital Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)we updated our model based on the 2Q financial results, and wereiterate our Buy rating and $30 PT

Stacy Ku

TD Cowen

―

Buy

―

Reiterated

07/31/25

TD Cowen Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Sean Laaman

Morgan Stanley

$27

Buy

23.57%

Upside

Reiterated

05/19/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from Morgan Stanley

Mayank Mamtani

B.Riley Financial

$33

Buy

51.03%

Upside

Reiterated

01/21/25

Analysts Conflicted on These Healthcare Names: Ironwood Pharma (NASDAQ: IRWD) and Centessa Pharmaceuticals (NASDAQ: CNTA)

Debjit Chattopadhyay

Guggenheim

$24→$28

Buy

28.15%

Upside

Reiterated

11/15/24

Centessa price target raised to $28 from $24 at GuggenheimCentessa price target raised to $28 from $24 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Risinger

Leerink Partners

$36

Buy

64.76%

Upside

Reiterated

09/11/25

Centessa Pharmaceuticals: Promising Prospects for ORX750 Justify Buy RatingWe anticipate disclosure of Ph2a results this fall, and we rate CNTA OP with a PT of $36.

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/09/25

Truist Financial Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)

Jay Olson

Oppenheimer

$40

Buy

83.07%

Upside

Reiterated

09/09/25

Kostas Biliouris

BMO Capital

$35

Buy

60.18%

Upside

Reiterated

09/08/25

Centessa Pharmaceuticals: Buy Rating Based on Promising Orexin Agonist Program and Market Potential

Clara Dong

Jefferies

$19→$27

Buy

23.57%

Upside

Reiterated

09/08/25

Jefferies Remains a Buy on Centessa Pharmaceuticals (CNTA)

Francois Brisebois

LifeSci Capital

$37→$39

Buy

78.49%

Upside

Reiterated

09/08/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from LifeSci Capital

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

09/03/25

Evercore ISI Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Benjamin Burnett

Wells Fargo

$31

Buy

41.88%

Upside

Initiated

09/03/25

Centessa initiated with an Overweight at Wells FargoCentessa initiated with an Overweight at Wells Fargo

Ami Fadia

Needham

―

Buy

―

Reiterated

08/20/25

We reiterate our Buy rating and continue to have conviction that CNTA could emerge with the best in class profile based on its wide therapeutic index.

Biren Amin

Piper Sandler

$38

Buy

73.91%

Upside

Reiterated

08/18/25

Piper Sandler Remains a Buy on Centessa Pharmaceuticals (CNTA)

Rudy Li

Chardan Capital

$30

Buy

37.30%

Upside

Reiterated

08/12/25

Chardan Capital Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)we updated our model based on the 2Q financial results, and wereiterate our Buy rating and $30 PT

Stacy Ku

TD Cowen

―

Buy

―

Reiterated

07/31/25

TD Cowen Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Sean Laaman

Morgan Stanley

$27

Buy

23.57%

Upside

Reiterated

05/19/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from Morgan Stanley

Mayank Mamtani

B.Riley Financial

$33

Buy

51.03%

Upside

Reiterated

01/21/25

Analysts Conflicted on These Healthcare Names: Ironwood Pharma (NASDAQ: IRWD) and Centessa Pharmaceuticals (NASDAQ: CNTA)

Debjit Chattopadhyay

Guggenheim

$24→$28

Buy

28.15%

Upside

Reiterated

11/15/24

Centessa price target raised to $28 from $24 at GuggenheimCentessa price target raised to $28 from $24 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Centessa Pharmaceuticals

1 Month

xxx

Success Rate

5/6 ratings generated profit

Average Return

+3.47%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 83.33% of your transactions generating a profit, with an average return of +3.47% per trade.

3 Months

xxx

Success Rate

19/23 ratings generated profit

Average Return

+23.73%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 82.61% of your transactions generating a profit, with an average return of +23.73% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

23/23 ratings generated profit

Average Return

+77.27%

reiterated a buy rating 8 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +77.27% per trade.

2 Years

xxx

Success Rate

23/23 ratings generated profit

Average Return

+122.00%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +122.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTA Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CNTA has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CNTA average Analyst price target in the past 3 months is 34.50.

Each month's total comprises the sum of three months' worth of ratings.

CNTA Financial Forecast

CNTA Earnings Forecast

Next quarter’s earnings estimate for CNTA is -$0.39 with a range of -$0.44 to -$0.30. The previous quarter’s EPS was -$0.38. CNTA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.

CNTA Sales Forecast

Next quarter’s sales forecast for CNTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CNTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.

CNTA Stock Forecast FAQ

What is CNTA’s average 12-month price target, according to analysts?

Based on analyst ratings, Centessa Pharmaceuticals’s 12-month average price target is 34.50.

What is CNTA’s upside potential, based on the analysts’ average price target?

Centessa Pharmaceuticals has 57.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CNTA a Buy, Sell or Hold?

Centessa Pharmaceuticals has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Centessa Pharmaceuticals’s price target?

The average price target for Centessa Pharmaceuticals is 34.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $27.00. The average price target represents 57.89% Increase from the current price of $21.85.

What do analysts say about Centessa Pharmaceuticals?

Centessa Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CNTA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

CNTA Analyst Ratings

CNTA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Centessa Pharmaceuticals

CNTA Analyst Recommendation Trends

CNTA Financial Forecast

CNTA Earnings Forecast

CNTA Sales Forecast

CNTA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts